| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.793 | 0.001 | 0.86 | Sphingosine 1-phosphate receptor 4 agonist | 0.218 0.004 DBMET03308 0.42 0.002 DBMET03309 0.604 0.001 DBMET03311 0.207 0.004 DBMET03310 0.86 0.001 DBMET03312 | DBMET03312 | |
| 0.7 | 0.001 | 0.7 | Sphingosine 1-phosphate receptor agonist | 0.177 0.004 DBMET03308 0.302 0.003 DBMET03309 0.566 0.001 DBMET03311 0.097 0.006 DBMET03310 0.595 0.001 DBMET03312 | ||
| 0.723 | 0.03 | 0.723 | Alpha-glucosidase inhibitor | 0.382 0.123 DBMET03308 0.723 0.03 DBMET03309 0.532 0.071 DBMET03311 0.347 0.137 DBMET03310 0.515 0.076 DBMET03312 | ||
| 0.64 | 0.001 | 0.64 | Sphingosine 1-phosphate receptor 1 agonist | 0.164 0.003 DBMET03308 0.247 0.003 DBMET03309 0.485 0.001 DBMET03311 0.08 0.006 DBMET03310 0.526 0.001 DBMET03312 | ||
| 0.643 | 0.045 | 0.699 | DNA directed DNA polymerase inhibitor | 0.315 0.155 DBMET03308 0.689 0.037 DBMET03309 0.489 0.086 DBMET03311 0.337 0.144 DBMET03310 0.699 0.035 DBMET03312 | DBMET03312 | |
| 0.448 | 0.01 | 0.54 | Dual specificity phosphatase inhibitor | 0.54 0.005 DBMET03309 0.449 0.01 DBMET03311 0.205 0.052 DBMET03310 0.478 0.007 DBMET03312 | DBMET03309 | |
| 0.432 | 0.002 | 0.459 | Sphingosine 1-phosphate receptor 3 agonist | 0.333 0.002 DBMET03308 0.459 0.002 DBMET03309 0.376 0.002 DBMET03311 0.313 0.003 DBMET03310 0.381 0.002 DBMET03312 | DBMET03309 | |
| 0.435 | 0.01 | 0.531 | Dual specificity phosphatase 3 inhibitor | 0.531 0.005 DBMET03309 0.442 0.01 DBMET03311 0.23 0.047 DBMET03310 0.483 0.008 DBMET03312 | DBMET03309 | |
| 0.464 | 0.097 | 0.701 | DNA polymerase beta inhibitor | 0.701 0.038 DBMET03309 0.452 0.1 DBMET03311 0.266 0.183 DBMET03310 0.698 0.039 DBMET03312 | DBMET03309 | |
| 0.412 | 0.058 | 0.434 | Immunosuppressant | 0.319 0.104 DBMET03308 0.352 0.086 DBMET03309 0.434 0.052 DBMET03311 0.336 0.094 DBMET03310 0.354 0.084 DBMET03312 | DBMET03311 | |
| 0.35 | 0.003 | 0.35 | Sphingosine 1-phosphate receptor 4 antagonist | 0.155 0.029 DBMET03308 0.218 0.006 DBMET03309 0.282 0.004 DBMET03311 0.141 0.042 DBMET03310 0.288 0.004 DBMET03312 | ||
| 0.326 | 0.019 | 0.456 | Mcl-1 antagonist | 0.456 0.007 DBMET03309 0.374 0.013 DBMET03311 0.224 0.045 DBMET03310 0.419 0.009 DBMET03312 | DBMET03309 | |
| 0.328 | 0.021 | 0.4 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.4 0.011 DBMET03309 0.275 0.035 DBMET03311 0.281 0.033 DBMET03310 0.301 0.027 DBMET03312 | DBMET03309 | |
| 0.245 | 0.004 | 0.245 | Sphingosine 1-phosphate receptor 5 antagonist | 0.149 0.064 DBMET03308 0.22 0.005 DBMET03309 0.209 0.008 DBMET03311 0.166 0.038 DBMET03310 0.238 0.004 DBMET03312 | ||
| 0.329 | 0.09 | 0.676 | Prostaglandin dehydrogenase inhibitor | 0.676 0.015 DBMET03309 0.339 0.086 DBMET03311 0.408 0.065 DBMET03310 0.529 0.036 DBMET03312 | DBMET03309 | |
| 0.226 | 0.003 | 0.276 | Sphingosine 1-phosphate receptor 1 antagonist | 0.062 0.026 DBMET03308 0.155 0.004 DBMET03309 0.175 0.004 DBMET03311 0.069 0.019 DBMET03310 0.276 0.003 DBMET03312 | DBMET03312 | |
| 0.222 | 0.004 | 0.285 | Sphingosine 1-phosphate receptor antagonist | 0.076 0.054 DBMET03308 0.166 0.005 DBMET03309 0.165 0.005 DBMET03311 0.084 0.039 DBMET03310 0.285 0.003 DBMET03312 | DBMET03312 | |
| 0.232 | 0.033 | 0.232 | Amylase inhibitor | 0.107 0.091 DBMET03311 | ||
| 0.203 | 0.004 | 0.242 | Sphingosine 1-phosphate receptor 5 agonist | 0.099 0.009 DBMET03308 0.195 0.004 DBMET03309 0.197 0.004 DBMET03311 0.121 0.006 DBMET03310 0.242 0.004 DBMET03312 | DBMET03312 | |
| 0.321 | 0.144 | 0.741 | Cyclophilin D inhibitor | 0.741 0.01 DBMET03308 0.461 0.063 DBMET03311 0.315 0.15 DBMET03312 | DBMET03308 | |
| 0.268 | 0.093 | 0.416 | Streptokinase A inhibitor | 0.224 0.119 DBMET03308 0.416 0.043 DBMET03309 0.265 0.095 DBMET03311 0.21 0.127 DBMET03310 0.297 0.08 DBMET03312 | DBMET03309 | |
| 0.22 | 0.046 | 0.266 | Amyloid beta precursor protein antagonist | 0.266 0.027 DBMET03309 0.213 0.049 DBMET03311 0.245 0.035 DBMET03312 | DBMET03309 | |
| 0.244 | 0.075 | 0.425 | Dyrk kinase inhibitor | 0.425 0.022 DBMET03309 0.181 0.11 DBMET03311 0.242 0.076 DBMET03310 0.232 0.081 DBMET03312 | DBMET03309 | |
| 0.161 | 0.015 | 0.176 | CDC-like kinase 3 inhibitor | 0.101 0.078 DBMET03308 0.176 0.011 DBMET03309 0.143 0.022 DBMET03311 0.168 0.013 DBMET03310 0.149 0.019 DBMET03312 | DBMET03309 | |
| 0.155 | 0.023 | 0.155 | Sphingosine 1-phosphate receptor 2 agonist | 0.138 0.033 DBMET03309 0.142 0.031 DBMET03311 0.112 0.07 DBMET03310 0.12 0.055 DBMET03312 | ||
| 0.181 | 0.055 | 0.266 | Protein-tyrosine phosphatase inhibitor | 0.253 0.03 DBMET03309 0.266 0.027 DBMET03311 0.25 0.031 DBMET03312 | DBMET03311 | |
| 0.133 | 0.019 | 0.168 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.168 0.01 DBMET03309 0.12 0.025 DBMET03311 0.15 0.014 DBMET03310 0.135 0.019 DBMET03312 | DBMET03309 | |
| 0.141 | 0.084 | 0.206 | Phospholipase A2 inhibitor | 0.136 0.091 DBMET03311 0.206 0.039 DBMET03312 | DBMET03312 | |
| 0.067 | 0.01 | 0.107 | Estrogen-related receptor alpha antagonist | 0.107 0.005 DBMET03309 0.062 0.01 DBMET03311 0.039 0.018 DBMET03310 0.092 0.007 DBMET03312 | DBMET03309 | |
| 0.184 | 0.129 | 0.412 | Hypoglycemic | 0.412 0.025 DBMET03308 0.236 0.086 DBMET03311 0.164 0.156 DBMET03312 | DBMET03308 | |
| 0.081 | 0.025 | 0.081 | Neuraminidase (influenza) inhibitor | |||
| 0.075 | 0.021 | 0.075 | Sphingosine 1-phosphate receptor 3 antagonist | 0.064 0.032 DBMET03311 0.074 0.022 DBMET03312 | ||
| 0.2 | 0.154 | 0.318 | Thyroid hormone beta antagonist | 0.189 0.164 DBMET03308 0.214 0.143 DBMET03309 0.178 0.176 DBMET03311 0.318 0.079 DBMET03312 | DBMET03312 | |
| 0.197 | 0.155 | 0.405 | 12-Lipoxygenase inhibitor | 0.405 0.038 DBMET03309 0.194 0.158 DBMET03311 0.207 0.144 DBMET03310 0.287 0.088 DBMET03312 | DBMET03309 | |
| 0.162 | 0.12 | 0.326 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.326 0.042 DBMET03309 0.157 0.125 DBMET03310 0.154 0.127 DBMET03312 | DBMET03309 | |
| 0.075 | 0.033 | 0.112 | CDC25B inhibitor | 0.112 0.013 DBMET03309 0.084 0.024 DBMET03311 0.066 0.042 DBMET03310 0.094 0.018 DBMET03312 | DBMET03309 | |
| 0.071 | 0.033 | 0.071 | Neuraminidase inhibitor | |||
| 0.131 | 0.095 | 0.21 | Insulin secretagoues | 0.21 0.031 DBMET03308 | DBMET03308 | |
| 0.199 | 0.165 | 0.248 | Cholesterol antagonist | 0.248 0.127 DBMET03308 | DBMET03308 | |
| 0.059 | 0.029 | 0.079 | DNA helicase inhibitor | 0.079 0.011 DBMET03309 0.072 0.016 DBMET03311 0.077 0.012 DBMET03312 | DBMET03309 | |
| 0.209 | 0.18 | 0.348 | Calpain 2 inhibitor | 0.265 0.139 DBMET03308 0.348 0.088 DBMET03309 0.201 0.187 DBMET03311 0.259 0.143 DBMET03312 | DBMET03309 | |
| 0.192 | 0.168 | 0.337 | Thyroid hormone antagonist | 0.244 0.128 DBMET03308 0.214 0.149 DBMET03309 0.337 0.078 DBMET03312 | DBMET03312 | |
| 0.08 | 0.062 | 0.093 | Thioredoxin reductase inhibitor | 0.093 0.037 DBMET03309 0.08 0.062 DBMET03311 0.078 0.067 DBMET03310 0.088 0.043 DBMET03312 | DBMET03309 | |
| 0.059 | 0.043 | 0.072 | Bcl-xL inhibitor | 0.072 0.018 DBMET03309 0.059 0.043 DBMET03311 0.064 0.03 DBMET03312 | DBMET03309 | |
| 0.038 | 0.024 | 0.044 | Glucose-6-phosphate dehydrogenase inhibitor | 0.044 0.016 DBMET03309 0.036 0.029 DBMET03311 0.035 0.034 DBMET03310 0.038 0.026 DBMET03312 | DBMET03309 | |
| 0.141 | 0.132 | 0.143 | P-glycoprotein inhibitor | 0.143 0.128 DBMET03308 | DBMET03308 | |
| 0.033 | 0.025 | 0.094 | RNA-directed RNA polymerase inhibitor | 0.093 0.005 DBMET03309 0.04 0.018 DBMET03311 0.094 0.005 DBMET03310 0.079 0.007 DBMET03312 | DBMET03310 | |
| 0.092 | 0.086 | 0.163 | Protein-tyrosine phosphatase 1B inhibitor | 0.133 0.054 DBMET03309 0.163 0.041 DBMET03311 0.139 0.05 DBMET03312 | DBMET03311 | |
| 0.028 | 0.024 | 0.101 | Thiazolidinedione | 0.101 0.002 DBMET03308 0.03 0.019 DBMET03309 0.032 0.015 DBMET03311 0.03 0.019 DBMET03312 | DBMET03308 | |
| 0.046 | 0.043 | 0.096 | Aldose reductase inhibitor | 0.068 0.028 DBMET03308 0.08 0.023 DBMET03309 0.073 0.026 DBMET03311 0.096 0.019 DBMET03312 | DBMET03312 | |
| 0.032 | 0.028 | 0.051 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.031 0.03 DBMET03311 0.051 0.009 DBMET03312 | DBMET03312 | |
| 0.216 | 0.213 | 0.511 | Transcription factor inhibitor | 0.511 0.072 DBMET03309 0.281 0.166 DBMET03311 0.238 0.195 DBMET03310 0.382 0.117 DBMET03312 | DBMET03309 | |
| 0.022 | 0.038 | 0.085 | HCV NS5B polymerase inhibitor | 0.082 0.006 DBMET03309 0.032 0.02 DBMET03311 0.085 0.005 DBMET03310 0.064 0.008 DBMET03312 | DBMET03310 | |
| 0.132 | 0.158 | 0.218 | Insulin sensitizer | 0.18 0.096 DBMET03308 0.218 0.056 DBMET03311 0.161 0.119 DBMET03312 | DBMET03311 | |
| 0.142 | 0.169 | 0.183 | Vasodilator | 0.183 0.119 DBMET03308 | DBMET03308 | |
| 0.096 | 0.129 | 0.146 | CDC-like kinase 1 inhibitor | 0.146 0.073 DBMET03309 0.115 0.101 DBMET03310 | DBMET03309 | |
| 0.049 | 0.082 | 0.068 | Bcl2 antagonist | 0.068 0.045 DBMET03309 | DBMET03309 | |
| 0.142 | 0.19 | 0.16 | MAP kinase kinase 5 inhibitor | 0.16 0.117 DBMET03308 | DBMET03308 | |
| 0.048 | 0.098 | 0.067 | Histone deacetylase SIRT1 stimulant | 0.067 0.058 DBMET03308 | DBMET03308 | |
| 0.048 | 0.098 | 0.067 | Histone deacetylase stimulant | 0.067 0.058 DBMET03308 | DBMET03308 | |
| 0.042 | 0.097 | 0.056 | Prostaglandin F2 alpha antagonist | 0.056 0.054 DBMET03311 | DBMET03311 | |
| 0.067 | 0.122 | 0.09 | Phosphodiesterase 7B inhibitor | 0.09 0.07 DBMET03309 | DBMET03309 | |
| 0.056 | 0.127 | 0.096 | 5-Lipoxygenase inhibitor | 0.094 0.068 DBMET03309 0.096 0.067 DBMET03312 | DBMET03312 | |
| 0.017 | 0.11 | 0.031 | Peroxisome proliferator-activated receptor delta antagonist | 0.031 0.028 DBMET03311 0.031 0.028 DBMET03312 | DBMET03312 | |
| 0.028 | 0.126 | 0.045 | CF transmembrane conductance regulator antagonist | 0.045 0.015 DBMET03309 | DBMET03309 | |
| 0.062 | 0.162 | 0.08 | Estrogen-related receptor beta agonist | 0.08 0.066 DBMET03309 | DBMET03309 | |
| 0.164 | 0.263 | 0.202 | Interleukin 2 agonist | 0.202 0.186 DBMET03312 | DBMET03312 | |
| 0.029 | 0.131 | 0.143 | Peroxisome proliferator-activated receptor gamma agonist | 0.143 0.014 DBMET03308 0.113 0.022 DBMET03311 0.068 0.05 DBMET03312 | DBMET03308 | |
| 0.13 | 0.232 | 0.29 | Lipoxygenase inhibitor | 0.273 0.085 DBMET03309 0.29 0.076 DBMET03312 | DBMET03312 | |
| 0.06 | 0.168 | 0.108 | Electrolyte absorption antagonist | 0.108 0.048 DBMET03310 | DBMET03310 | |
| 0.094 | 0.217 | 0.181 | Interleukin 6 antagonist | 0.181 0.054 DBMET03308 | DBMET03308 | |
| 0.078 | 0.205 | 0.141 | Cell wall synthesis inhibitor | 0.141 0.074 DBMET03310 | DBMET03310 | |
| 0.141 | 0.287 | 0.36 | Sodium/bile acid cotransporter inhibitor | 0.36 0.034 DBMET03308 | DBMET03308 | |
| 0.054 | 0.205 | 0.112 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.112 0.108 DBMET03309 | DBMET03309 | |
| 0.04 | 0.198 | 0.073 | Peroxisome proliferator-activated receptor gamma antagonist | 0.066 0.064 DBMET03311 0.073 0.045 DBMET03312 | DBMET03312 | |
| 0.085 | 0.244 | 0.324 | Hypolipemic | 0.324 0.042 DBMET03308 | DBMET03308 | |
| 0.084 | 0.245 | 0.41 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.41 0.036 DBMET03309 0.212 0.093 DBMET03310 0.151 0.14 DBMET03312 | DBMET03309 | |
| 0.08 | 0.244 | 0.12 | Vanilloid 1 agonist | 0.12 0.087 DBMET03309 | DBMET03309 | |
| 0.063 | 0.233 | 0.09 | Folate antagonist | 0.09 0.087 DBMET03312 | DBMET03312 | |
| 0.029 | 0.204 | 0.058 | Glucosylceramidase inhibitor | 0.058 0.033 DBMET03310 | DBMET03310 | |
| 0.007 | 0.183 | 0.033 | Estradiol 17 beta-dehydrogenase 3 inhibitor | 0.033 0.021 DBMET03309 | DBMET03309 | |
| 0.138 | 0.319 | 0.253 | Antibacterial | 0.253 0.174 DBMET03309 | DBMET03309 | |
| 0.1 | 0.284 | 0.217 | Beta lactamase inhibitor | 0.217 0.175 DBMET03312 | DBMET03312 | |
| 0.004 | 0.195 | 0.016 | Free fatty acid receptor 1 agonist | 0.016 0.014 DBMET03308 | DBMET03308 | |
| 0.121 | 0.326 | 0.244 | Insulysin inhibitor | 0.244 0.102 DBMET03309 0.219 0.131 DBMET03312 | DBMET03309 | |
| 0.052 | 0.27 | 0.106 | Estrogen antagonist | 0.106 0.083 DBMET03309 | DBMET03309 | |
| 0.046 | 0.274 | 0.097 | ABCA1 expression enhancer | 0.097 0.054 DBMET03308 | DBMET03308 | |
| 0.041 | 0.273 | 0.114 | Alkaline phosphatase inhibitor | 0.114 0.094 DBMET03309 | DBMET03309 | |
| 0.014 | 0.248 | 0.057 | Maillard reaction inhibitor | 0.057 0.037 DBMET03308 | DBMET03308 | |
| 0.077 | 0.342 | 0.2 | Thioredoxin glutathione reductase inhibitor | 0.2 0.173 DBMET03309 | DBMET03309 | |
| 0.086 | 0.359 | 0.187 | Transcription factor STAT3 inhibitor | 0.187 0.154 DBMET03310 | DBMET03310 | |
| 0.057 | 0.337 | 0.177 | Platelet antagonist | 0.177 0.12 DBMET03312 | DBMET03312 | |
| 0.046 | 0.354 | 0.154 | Heat shock protein 90 antagonist | 0.154 0.071 DBMET03309 | DBMET03309 | |
| 0.031 | 0.351 | 0.093 | Estrogen receptor beta antagonist | 0.093 0.077 DBMET03309 | DBMET03309 | |
| 0.005 | 0.355 | 0.033 | 1,3-Beta-glucan synthase inhibitor | 0.033 0.009 DBMET03310 | DBMET03310 | |
| 0.018 | 0.394 | 0.093 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.093 0.013 DBMET03309 | DBMET03309 | |
| 0.037 | 0.414 | 0.217 | Heat shock protein 90 alpha antagonist | 0.217 0.04 DBMET03309 | DBMET03309 | |
| 0.088 | 0.605 | 0.193 | 5 Hydroxytryptamine uptake stimulant | 0.186 0.181 DBMET03309 0.193 0.166 DBMET03310 | DBMET03310 | |
| 0.041 | 0.568 | 0.207 | Transcription factor STAT inhibitor | 0.207 0.128 DBMET03310 | DBMET03310 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |